US6329381B1
(en)
|
1997-11-28 |
2001-12-11 |
Sumitomo Pharmaceuticals Company, Limited |
Heterocyclic compounds
|
ZA9810490B
(en)
|
1997-12-03 |
1999-05-20 |
Dainippon Pharmaceutical Co |
2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
|
TW572758B
(en)
*
|
1997-12-22 |
2004-01-21 |
Sumitomo Pharma |
Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
|
KR100377138B1
(ko)
*
|
1998-11-10 |
2003-06-12 |
주식회사 엘지생명과학 |
퓨린구조를갖는싸이클린의존키나아제저해제,그제조방법및그를함유하는항암제조성물
|
CZ27399A3
(cs)
*
|
1999-01-26 |
2000-08-16 |
Ústav Experimentální Botaniky Av Čr |
Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
|
US6558951B1
(en)
*
|
1999-02-11 |
2003-05-06 |
3M Innovative Properties Company |
Maturation of dendritic cells with immune response modifying compounds
|
KR100829297B1
(ko)
*
|
2000-07-31 |
2008-05-13 |
다이닛본 스미토모 세이야꾸 가부시끼가이샤 |
2-아릴-8-옥소디히드로푸린 유도체를 유효성분으로 하는치매증 치료제
|
JP2008531580A
(ja)
*
|
2000-12-08 |
2008-08-14 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答修飾因子の標的化送達のための組成物および方法
|
US6677347B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
EP1386923B1
(en)
*
|
2001-04-17 |
2008-08-13 |
Dainippon Sumitomo Pharma Co., Ltd. |
Novel adenine derivatives
|
US20030133913A1
(en)
*
|
2001-08-30 |
2003-07-17 |
3M Innovative Properties Company |
Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
|
WO2003037860A2
(en)
|
2001-10-30 |
2003-05-08 |
Conforma Therapeutics Corporation |
Purine analogs having hsp90-inhibiting activity
|
DK1719511T3
(da)
*
|
2001-11-16 |
2009-04-14 |
Coley Pharm Group Inc |
N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf
|
US7321033B2
(en)
*
|
2001-11-27 |
2008-01-22 |
Anadys Pharmaceuticals, Inc. |
3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
|
CA2365732A1
(en)
*
|
2001-12-20 |
2003-06-20 |
Ibm Canada Limited-Ibm Canada Limitee |
Testing measurements
|
EP1478327B1
(en)
*
|
2002-02-22 |
2015-04-29 |
Meda AB |
Method of reducing and treating uvb-induced immunosuppression
|
DK1545597T3
(da)
|
2002-08-15 |
2011-01-31 |
3M Innovative Properties Co |
Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
|
EP1550662B1
(en)
*
|
2002-09-27 |
2012-07-04 |
Dainippon Sumitomo Pharma Co., Ltd. |
Adenine compound and use thereof
|
WO2004053452A2
(en)
*
|
2002-12-11 |
2004-06-24 |
3M Innovative Properties Company |
Assays relating to toll-like receptor activity
|
WO2004053057A2
(en)
*
|
2002-12-11 |
2004-06-24 |
3M Innovative Properties Company |
Gene expression systems and recombinant cell lines
|
US7387271B2
(en)
|
2002-12-30 |
2008-06-17 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
US7375180B2
(en)
*
|
2003-02-13 |
2008-05-20 |
3M Innovative Properties Company |
Methods and compositions related to IRM compounds and Toll-like receptor 8
|
EP1599726A4
(en)
*
|
2003-02-27 |
2009-07-22 |
3M Innovative Properties Co |
SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
|
EP1601365A4
(en)
|
2003-03-04 |
2009-11-11 |
3M Innovative Properties Co |
PROPHYLACTIC TREATMENT OF UV-INDUCED EPIDERMAL NEOPLASIA
|
JP2006520245A
(ja)
*
|
2003-03-13 |
2006-09-07 |
スリーエム イノベイティブ プロパティズ カンパニー |
入れ墨の除去方法
|
US8426457B2
(en)
*
|
2003-03-13 |
2013-04-23 |
Medicis Pharmaceutical Corporation |
Methods of improving skin quality
|
US20040192585A1
(en)
*
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
US7923560B2
(en)
*
|
2003-04-10 |
2011-04-12 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
EP1615926A1
(en)
*
|
2003-04-21 |
2006-01-18 |
Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky |
(purin-6-yl) amino acid and production method thereof
|
US20040214851A1
(en)
*
|
2003-04-28 |
2004-10-28 |
3M Innovative Properties Company |
Compositions and methods for induction of opioid receptors
|
EP1651035A2
(en)
*
|
2003-07-31 |
2006-05-03 |
3M Innovative Properties Company |
Compositions for encapsulation and controlled release
|
CN1852711A
(zh)
*
|
2003-08-05 |
2006-10-25 |
3M创新有限公司 |
使用免疫响应调节化合物的传染病预防
|
BRPI0412902A
(pt)
*
|
2003-08-12 |
2006-09-26 |
3M Innovative Properties Co |
compostos contendo imidazo substituìdo por oxima
|
JP2007504145A
(ja)
*
|
2003-08-25 |
2007-03-01 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫刺激性の組み合わせおよび治療
|
AU2004268616B2
(en)
*
|
2003-08-25 |
2010-10-07 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
CA2536136C
(en)
*
|
2003-08-27 |
2012-10-30 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted imidazoquinolines
|
EP1663222A4
(en)
*
|
2003-09-02 |
2008-05-21 |
3M Innovative Properties Co |
METHODS RELATING TO THE TREATMENT OF GIANCES
|
AU2004270201A1
(en)
*
|
2003-09-05 |
2005-03-17 |
3M Innovative Properties Company |
Treatment for CD5+ B cell lymphoma
|
US7576068B2
(en)
|
2003-09-05 |
2009-08-18 |
Anadys Pharmaceuticals, Inc. |
Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
|
US20050059072A1
(en)
*
|
2003-09-17 |
2005-03-17 |
3M Innovative Properties Company |
Selective modulation of TLR gene expression
|
WO2005028434A2
(en)
|
2003-09-18 |
2005-03-31 |
Conforma Therapeutics Corporation |
Novel heterocyclic compounds as hsp90-inhibitors
|
US7544697B2
(en)
*
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
CA2540541C
(en)
*
|
2003-10-03 |
2012-03-27 |
3M Innovative Properties Company |
Alkoxy substituted imidazoquinolines
|
US20090075980A1
(en)
*
|
2003-10-03 |
2009-03-19 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and Analogs Thereof
|
US20050096259A1
(en)
*
|
2003-10-31 |
2005-05-05 |
3M Innovative Properties Company |
Neutrophil activation by immune response modifier compounds
|
US8598192B2
(en)
*
|
2003-11-14 |
2013-12-03 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazoquinolines
|
WO2005048933A2
(en)
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Oxime substituted imidazo ring compounds
|
JP4440891B2
(ja)
*
|
2003-11-25 |
2010-03-24 |
日本曹達株式会社 |
アデニン誘導体の製造方法
|
AU2004293078B2
(en)
*
|
2003-11-25 |
2012-01-19 |
3M Innovative Properties Company |
Substituted imidazo ring systems and methods
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
JP2007513165A
(ja)
*
|
2003-12-02 |
2007-05-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
Irm化合物を含む併用薬および治療方法
|
EP1697363A2
(en)
*
|
2003-12-16 |
2006-09-06 |
Ranbaxy Laboratories Limited |
Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors
|
EP1701955A1
(en)
|
2003-12-29 |
2006-09-20 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
WO2005066169A2
(en)
*
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
EP1699398A4
(en)
*
|
2003-12-30 |
2007-10-17 |
3M Innovative Properties Co |
IMPROVING THE IMMUNE RESPONSE
|
CA2559863A1
(en)
*
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
US8012964B2
(en)
|
2004-03-26 |
2011-09-06 |
Dainippon Sumitomo Pharma Co., Ltd. |
9-substituted 8-oxoadenine compound
|
JPWO2005092892A1
(ja)
*
|
2004-03-26 |
2008-02-14 |
大日本住友製薬株式会社 |
8−オキソアデニン化合物
|
WO2005110013A2
(en)
*
|
2004-04-09 |
2005-11-24 |
3M Innovative Properties Company |
Methods, compositions, and preparations for delivery of immune response modifiers
|
MXPA06012451A
(es)
*
|
2004-04-28 |
2007-01-31 |
3M Innovative Properties Co |
Composiciones y metodos para vacunacion por la mucosa.
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
ES2560449T3
(es)
|
2004-05-28 |
2016-02-19 |
Oryxe |
Una mezcla para administración transdérmica de compuestos de peso molecular bajo y alto
|
WO2005123080A2
(en)
*
|
2004-06-15 |
2005-12-29 |
3M Innovative Properties Company |
Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
US7915281B2
(en)
*
|
2004-06-18 |
2011-03-29 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
|
WO2006009832A1
(en)
*
|
2004-06-18 |
2006-01-26 |
3M Innovative Properties Company |
Substituted imidazo ring systems and methods
|
WO2006038923A2
(en)
*
|
2004-06-18 |
2006-04-13 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
US8026366B2
(en)
*
|
2004-06-18 |
2011-09-27 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
WO2006026470A2
(en)
*
|
2004-08-27 |
2006-03-09 |
3M Innovative Properties Company |
Hiv immunostimulatory compositions
|
WO2006026760A2
(en)
*
|
2004-09-02 |
2006-03-09 |
3M Innovative Properties Company |
1-amino imidazo-containing compounds and methods
|
WO2006029223A2
(en)
*
|
2004-09-08 |
2006-03-16 |
Children's Medical Center Corporation |
Method for stimulating the immune response of newborns
|
JP2008515928A
(ja)
*
|
2004-10-08 |
2008-05-15 |
スリーエム イノベイティブ プロパティズ カンパニー |
Dnaワクチンのためのアジュバント
|
WO2006063072A2
(en)
*
|
2004-12-08 |
2006-06-15 |
3M Innovative Properties Company |
Immunomodulatory compositions, combinations and methods
|
WO2006066080A1
(en)
|
2004-12-17 |
2006-06-22 |
Anadys Pharmaceuticals, Inc. |
3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
|
ES2392648T3
(es)
|
2004-12-30 |
2012-12-12 |
3M Innovative Properties Company |
Compuestos quirales sustituidos que contienen un núcleo 1,2-imidazo-4,5-c condensado
|
US7943609B2
(en)
*
|
2004-12-30 |
2011-05-17 |
3M Innovative Proprerties Company |
Chiral fused [1,2]imidazo[4,5-C] ring compounds
|
CA2594253C
(en)
*
|
2004-12-30 |
2015-08-11 |
3M Innovative Properties Company |
Treatment for cutaneous metastases
|
US9248127B2
(en)
*
|
2005-02-04 |
2016-02-02 |
3M Innovative Properties Company |
Aqueous gel formulations containing immune response modifiers
|
EP1846405A2
(en)
|
2005-02-11 |
2007-10-24 |
3M Innovative Properties Company |
Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
|
CN101180297A
(zh)
|
2005-03-30 |
2008-05-14 |
康福玛医药公司 |
作为hsp90-抑制剂的炔基吡咯并嘧啶及相关类似物
|
AU2006232377A1
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridine-1,4-diamines and analogs thereof
|
CA2602590A1
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
US20080193474A1
(en)
*
|
2005-04-25 |
2008-08-14 |
Griesgraber George W |
Immunostimulatory Compositions
|
BRPI0611435A2
(pt)
|
2005-05-04 |
2010-09-08 |
Pfizer Ltd |
derivados de 2-amido-6-amino-8-oxopurina, composições farmacêuticas, uso e processo de preparo dos mesmos
|
JP4584335B2
(ja)
*
|
2005-09-02 |
2010-11-17 |
ファイザー・インク |
ヒドロキシ置換1h−イミダゾピリジンおよび方法
|
TW200801003A
(en)
*
|
2005-09-16 |
2008-01-01 |
Astrazeneca Ab |
Novel compounds
|
US20080269240A1
(en)
*
|
2005-09-22 |
2008-10-30 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel Adenine Compound
|
US20090099216A1
(en)
*
|
2005-09-22 |
2009-04-16 |
Astrazeneca Aktiebolag A Corporation Of Sweden |
Novel adenine compound
|
JPWO2007034817A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
WO2007034881A1
(ja)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規アデニン化合物
|
TW200745114A
(en)
*
|
2005-09-22 |
2007-12-16 |
Astrazeneca Ab |
Novel compounds
|
US20090105212A1
(en)
|
2005-09-22 |
2009-04-23 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel adenine compound
|
KR20080090400A
(ko)
|
2005-11-21 |
2008-10-08 |
애나디스 파마슈티칼스, 인코포레이티드 |
5-아미노-3H-티아졸로[4,5-d]피리미딘-2-온의 제조 방법
|
JPWO2007060918A1
(ja)
|
2005-11-24 |
2009-05-07 |
大日本住友製薬株式会社 |
新規なメモリーctl誘導増強剤
|
EP1988896A4
(en)
*
|
2006-02-22 |
2011-07-27 |
3M Innovative Properties Co |
CONJUGATES TO MODIFY IMMUNE REACTIONS
|
CA2655904C
(en)
|
2006-06-22 |
2014-11-18 |
Anadys Pharmaceuticals, Inc. |
Prodrugs of 5-amino-3-(3'-deoxy-.beta.-d-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
|
US8138172B2
(en)
*
|
2006-07-05 |
2012-03-20 |
Astrazeneca Ab |
8-oxoadenine derivatives acting as modulators of TLR7
|
WO2008008432A2
(en)
*
|
2006-07-12 |
2008-01-17 |
Coley Pharmaceutical Group, Inc. |
Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
|
ATE499940T1
(de)
|
2006-07-18 |
2011-03-15 |
Anadys Pharmaceuticals Inc |
Carbonat- und carbamat-prodrugs von thiazolo ä4,5-dü-pyrimidinen
|
JP5513118B2
(ja)
*
|
2006-10-19 |
2014-06-04 |
シグナル ファーマシューティカルズ,エルエルシー |
ヘテロアリール化合物、その組成物、及びプロテインキナーゼ阻害剤としてのそれらの使用
|
TW200831105A
(en)
*
|
2006-12-14 |
2008-08-01 |
Astrazeneca Ab |
Novel compounds
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
PT2132209E
(pt)
*
|
2007-03-19 |
2014-04-15 |
Astrazeneca Ab |
Compostos de 8-oxo-adenina substituídos na posição 9, como moduladores do recetor de tipo ¿toll¿ (tlr7)
|
JP5329444B2
(ja)
*
|
2007-03-19 |
2013-10-30 |
アストラゼネカ・アクチエボラーグ |
Toll様受容体(tlr7)モジュレーターとしての9−置換−8−オキソ−アデニン化合物
|
TW200902018A
(en)
|
2007-03-20 |
2009-01-16 |
Dainippon Sumitomo Pharma Co |
Novel adenine compound
|
EP2138497A4
(en)
|
2007-03-20 |
2012-01-04 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
GB0708258D0
(en)
*
|
2007-04-27 |
2007-06-06 |
Katholleke Universiteit Leuven |
New anti-viral nulceoside analogs
|
PL2155743T3
(pl)
*
|
2007-05-08 |
2013-01-31 |
Astrazeneca Ab |
Imidazochinoliny o właściwościach immunomodulacyjnych
|
PE20091236A1
(es)
|
2007-11-22 |
2009-09-16 |
Astrazeneca Ab |
Derivados de pirimidina como immunomoduladores de tlr7
|
PE20091156A1
(es)
|
2007-12-17 |
2009-09-03 |
Astrazeneca Ab |
Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
|
JPWO2009091031A1
(ja)
*
|
2008-01-17 |
2011-05-26 |
大日本住友製薬株式会社 |
アデニン化合物の製造方法
|
KR20100125245A
(ko)
*
|
2008-01-17 |
2010-11-30 |
다이닛본 스미토모 세이야꾸 가부시끼가이샤 |
아데닌 화합물의 제조 방법
|
UY32306A
(es)
|
2008-12-09 |
2010-07-30 |
Gilead Sciences Inc |
Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
|
GB0908772D0
(en)
*
|
2009-05-21 |
2009-07-01 |
Astrazeneca Ab |
New salts 756
|
WO2010133885A1
(en)
|
2009-05-21 |
2010-11-25 |
Astrazeneca Ab |
Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
|
CN104945420A
(zh)
|
2009-06-29 |
2015-09-30 |
因塞特公司 |
作为pi3k抑制剂的嘧啶酮类
|
US20110033515A1
(en)
*
|
2009-08-04 |
2011-02-10 |
Rst Implanted Cell Technology |
Tissue contacting material
|
EA023536B1
(ru)
*
|
2009-08-07 |
2016-06-30 |
Глаксосмитклайн Байолоджикалс Са |
Производные оксоаденина, конъюгированные с фосфо- или фосфонолипидами
|
CN102656172B
(zh)
*
|
2009-09-09 |
2016-03-23 |
大日本住友制药株式会社 |
8-氧代二氢嘌呤衍生物
|
US8507507B2
(en)
|
2009-10-22 |
2013-08-13 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
EP2507237A1
(en)
*
|
2009-12-03 |
2012-10-10 |
Dainippon Sumitomo Pharma Co., Ltd. |
Imidazoquinolines which act via toll - like receptors (tlr)
|
TW201130842A
(en)
*
|
2009-12-18 |
2011-09-16 |
Incyte Corp |
Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
|
US8759359B2
(en)
*
|
2009-12-18 |
2014-06-24 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as PI3K inhibitors
|
JP5816678B2
(ja)
|
2010-04-14 |
2015-11-18 |
インサイト・コーポレイションIncyte Corporation |
PI3Kδ阻害剤としての縮合誘導体
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
EP2651937B8
(en)
|
2010-12-16 |
2016-07-13 |
Sumitomo Dainippon Pharma Co., Ltd. |
Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy
|
WO2012080730A1
(en)
|
2010-12-17 |
2012-06-21 |
Astrazeneca Ab |
Purine derivatives
|
AR084366A1
(es)
|
2010-12-20 |
2013-05-08 |
Incyte Corp |
N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
|
JP2014076947A
(ja)
*
|
2011-02-03 |
2014-05-01 |
Dainippon Sumitomo Pharma Co Ltd |
2−オキシ置換8−オキソジヒドロプリン誘導体
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
WO2012135009A1
(en)
|
2011-03-25 |
2012-10-04 |
Incyte Corporation |
Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
|
ES2887303T3
(es)
|
2011-04-08 |
2021-12-22 |
Janssen Sciences Ireland Unlimited Co |
Derivados de pirimidina para el tratamiento de infecciones víricas
|
CA2835229C
(en)
|
2011-05-18 |
2020-05-05 |
Janssen R&D Ireland |
Quinazoline derivatives for the treatment of viral infections and further diseases
|
CN103582496B
(zh)
|
2011-06-03 |
2016-05-11 |
3M创新有限公司 |
具有聚乙二醇链段的异双官能连接基以及由其制成的免疫应答调节剂缀合物
|
AU2012261959B2
(en)
|
2011-06-03 |
2015-12-03 |
Solventum Intellectual Properties Company |
Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom
|
US20130023736A1
(en)
|
2011-07-21 |
2013-01-24 |
Stanley Dale Harpstead |
Systems for drug delivery and monitoring
|
HUE043703T2
(hu)
|
2011-09-02 |
2019-09-30 |
Incyte Holdings Corp |
Heterociklusos aminok PI3K inhibitorokként
|
MX347596B
(es)
*
|
2011-11-09 |
2017-05-03 |
Janssen Sciences Ireland Uc |
Derivados de purina para el tratamiento de infecciones viricas.
|
EA039373B1
(ru)
|
2012-02-08 |
2022-01-19 |
Янссен Сайенсиз Айрлэнд Юси |
Производные пиперидино-пиримидина для лечения вирусных инфекций
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
AU2013261267B2
(en)
|
2012-05-18 |
2017-06-29 |
Sumitomo Pharma Co., Ltd. |
Carboxylic acid compounds
|
JP6250046B2
(ja)
|
2012-07-13 |
2017-12-20 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
ウイルス感染症の処置のための大環状プリン
|
KR102280589B1
(ko)
|
2012-08-10 |
2021-07-22 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염 또는 추가 질환의 치료를 위한 알킬피리미딘 유도체
|
EP2712866A1
(en)
|
2012-10-01 |
2014-04-02 |
Centre National de la Recherche Scientifique (CNRS) |
1,2,4-triazine derivatives for the treatment of viral infections
|
BR112015007586B1
(pt)
|
2012-10-10 |
2021-02-09 |
Janssen Sciences Ireland Uc |
derivados de pirrolo[3,2-d]pirimidina, seu uso e composição farmacêutica que os compreende
|
DK2925729T3
(en)
|
2012-11-16 |
2018-01-22 |
Janssen Sciences Ireland Uc |
HETEROCYCLIC SUBSTITUTED 2-AMINOQUINAZOLINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
|
EP3756669A1
(en)
|
2013-01-07 |
2020-12-30 |
The Trustees of the University of Pennsylvania |
Compositions for use for treating cutaneous t cell lymphoma
|
CN103012405A
(zh)
*
|
2013-01-17 |
2013-04-03 |
苏春华 |
一种腺嘌呤类新化合物
|
JP6487854B2
(ja)
|
2013-02-08 |
2019-03-20 |
ヴァクシネックス, インコーポレイテッド |
修飾された糖脂質並びにその製造および使用方法
|
AU2014220717B2
(en)
|
2013-02-21 |
2018-03-29 |
Janssen Sciences Ireland Uc |
2-aminopyrimidine derivatives for the treatment of viral infections
|
MX366481B
(es)
|
2013-03-29 |
2019-07-09 |
Janssen Sciences Ireland Uc |
Deaza-purinonas macrociclicas para el tratamiento de infecciones virales.
|
EA034674B1
(ru)
|
2013-05-24 |
2020-03-05 |
Янссен Сайенсиз Айрлэнд Юси |
Производные пиридона для лечения нарушений, в которое вовлечены модуляции tlr7 и/или tlr8
|
UA117590C2
(uk)
|
2013-06-27 |
2018-08-27 |
ЯНССЕН САЙЄНСЕЗ АЙРЛЕНД ЮСі |
ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ
|
EA036162B1
(ru)
|
2013-07-30 |
2020-10-08 |
Янссен Сайенсиз Айрлэнд Юси |
Производные тиено[3,2-d]пиримидинов для лечения вирусных инфекций
|
US10077277B2
(en)
|
2014-06-11 |
2018-09-18 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
|
TWI806081B
(zh)
|
2014-07-11 |
2023-06-21 |
美商基利科學股份有限公司 |
用於治療HIV之toll樣受體調節劑
|
SG10201809918RA
(en)
|
2014-08-15 |
2018-12-28 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
Pyrrolopyrimidine compounds used as tlr7 agonist
|
PT3194401T
(pt)
|
2014-09-16 |
2020-12-23 |
Gilead Sciences Inc |
Formas sólidas de modulador de recetor tipo toll
|
TWI764392B
(zh)
|
2015-02-27 |
2022-05-11 |
美商英塞特公司 |
Pi3k抑制劑之鹽及製備方法
|
US9732097B2
(en)
|
2015-05-11 |
2017-08-15 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
WO2016183063A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Crystalline forms of a pi3k inhibitor
|
US11260018B2
(en)
|
2015-09-17 |
2022-03-01 |
Jrx Biotechnology, Inc. |
Approaches for improving skin hydration and moisturization
|
WO2017059280A1
(en)
|
2015-10-02 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Novel pan-tam inhibitors and mer/axl dual inhibitors
|
TWI558709B
(zh)
*
|
2015-10-07 |
2016-11-21 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
Pyrrolopyrimidine ring compounds, their use and pharmaceutical compositions
|
CN107043380A
(zh)
|
2016-02-05 |
2017-08-15 |
正大天晴药业集团股份有限公司 |
一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
|
WO2018002319A1
(en)
|
2016-07-01 |
2018-01-04 |
Janssen Sciences Ireland Uc |
Dihydropyranopyrimidines for the treatment of viral infections
|
SI3504210T1
(sl)
|
2016-08-29 |
2021-08-31 |
F. Hoffmann-La Roche Ag |
7-substituirane sulfonimidoilpurinonske spojine za zdravljenje virusne okužbe in zaščito pred njo
|
SG10202010317VA
(en)
|
2016-09-29 |
2020-11-27 |
Janssen Sciences Ireland Unlimited Co |
Pyrimidine prodrugs for the treatment of viral infections and further diseases
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
BR112019011284A2
(pt)
|
2016-12-05 |
2019-10-22 |
Apros Therapeutics Inc |
composto, composição farmacêutica, métodos de tratamento de uma condição, de hbv e de câncer, e, uso de um composto.
|
EP3603619A4
(en)
|
2017-03-29 |
2020-12-09 |
Sumitomo Dainippon Pharma Co., Ltd. |
VACCINAL ADJUVANT FORMULATION
|
US10508115B2
(en)
|
2017-08-16 |
2019-12-17 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
|
US10472361B2
(en)
|
2017-08-16 |
2019-11-12 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
|
US10487084B2
(en)
|
2017-08-16 |
2019-11-26 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
|
US10457681B2
(en)
|
2017-08-16 |
2019-10-29 |
Bristol_Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
|
US10494370B2
(en)
|
2017-08-16 |
2019-12-03 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
|
AU2018391899A1
(en)
|
2017-12-21 |
2020-07-02 |
Sumitomo Pharma Co., Ltd. |
Combination drug including TLR7 agonist
|
JP7328977B2
(ja)
|
2018-02-12 |
2023-08-17 |
エフ. ホフマン-ラ ロシュ アーゲー |
ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
|
JP2021516045A
(ja)
|
2018-02-28 |
2021-07-01 |
ファイザー・インク |
Il−15バリアントおよびその使用
|
TW201945003A
(zh)
|
2018-03-01 |
2019-12-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
2,4-二胺基喹唑啉衍生物及其醫學用途
|
WO2019209811A1
(en)
|
2018-04-24 |
2019-10-31 |
Bristol-Myers Squibb Company |
Macrocyclic toll-like receptor 7 (tlr7) agonists
|
AU2019274654B2
(en)
|
2018-05-23 |
2023-07-20 |
Pfizer Inc. |
Antibodies specific for CD3 and uses thereof
|
TWI803637B
(zh)
|
2018-05-23 |
2023-06-01 |
美商輝瑞大藥廠 |
特異性針對gucy2c之抗體及其用途
|
US10857153B2
(en)
|
2018-06-04 |
2020-12-08 |
Apros Therapeutics, Inc. |
Pyrimidine compounds containing acidic groups
|
WO2020022272A1
(ja)
|
2018-07-23 |
2020-01-30 |
公益財団法人ヒューマンサイエンス振興財団 |
インフルエンザワクチンを含む組成物
|
US11554120B2
(en)
|
2018-08-03 |
2023-01-17 |
Bristol-Myers Squibb Company |
1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
|
US20220370606A1
(en)
|
2018-12-21 |
2022-11-24 |
Pfizer Inc. |
Combination Treatments Of Cancer Comprising A TLR Agonist
|
WO2020190622A1
(en)
|
2019-03-15 |
2020-09-24 |
Rhodia Operations |
Polymer compositions and use of the same
|
WO2020255039A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
|
WO2021124073A1
(en)
|
2019-12-17 |
2021-06-24 |
Pfizer Inc. |
Antibodies specific for cd47, pd-l1, and uses thereof
|
US20230140430A1
(en)
|
2020-01-27 |
2023-05-04 |
Bristol-Myers Squibb Company |
1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
|
CN115135655A
(zh)
|
2020-01-27 |
2022-09-30 |
百时美施贵宝公司 |
作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
|
EP4097105A1
(en)
|
2020-01-27 |
2022-12-07 |
Bristol-Myers Squibb Company |
1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
|
JP2023512227A
(ja)
|
2020-01-27 |
2023-03-24 |
ブリストル-マイヤーズ スクイブ カンパニー |
トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物
|
JP2023512208A
(ja)
|
2020-01-27 |
2023-03-24 |
ブリストル-マイヤーズ スクイブ カンパニー |
トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物
|
WO2021154668A1
(en)
|
2020-01-27 |
2021-08-05 |
Bristol-Myers Squibb Company |
1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
|
KR20220132589A
(ko)
|
2020-01-27 |
2022-09-30 |
브리스톨-마이어스 스큅 컴퍼니 |
톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
|
CN115151548A
(zh)
|
2020-01-27 |
2022-10-04 |
百时美施贵宝公司 |
作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
|
JP2023512230A
(ja)
|
2020-01-27 |
2023-03-24 |
ブリストル-マイヤーズ スクイブ カンパニー |
トール様受容体7(TLR7)アゴニストとしてのC3置換1H-ピラゾロ[4,3-d]ピリミジン化合物
|
TW202216779A
(zh)
|
2020-07-17 |
2022-05-01 |
美商輝瑞股份有限公司 |
治療性抗體類和彼等之用途
|
CN114524815B
(zh)
*
|
2022-02-23 |
2023-05-23 |
华南理工大学 |
一种8-烷氧基嘌呤衍生物及其制备方法与应用
|